Valuation : Defence Therapeutics Inc.

Market Cap 33.35M 23.97M 20.71M 19.39M 17.72M 2.29B 33.52M 230M 89.69M 1.16B 90.06M 88.1M 3.84B P/E 2024
-2.5x
P/E 2025 -9.9x
Enterprise Value 33.62M 24.16M 20.88M 19.54M 17.87M 2.31B 33.79M 232M 90.42M 1.17B 90.79M 88.82M 3.87B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
66.13%
Yield 2024 *
-
Yield 2025 -
1 day+1.96%
1 week+1.96%
Current month+30.00%
1 month+23.81%
3 months-3.70%
6 months-14.75%
Current year-27.78%
1 week 0.5
Extreme 0.5
0.56
1 month 0.37
Extreme 0.37
0.59
Current year 0.36
Extreme 0.365
0.74
1 year 0.36
Extreme 0.365
0.93
3 years 0.36
Extreme 0.365
3.04
5 years 0.36
Extreme 0.365
8.15
10 years 0.36
Extreme 0.365
8.15
Manager TitleAgeSince
Chief Executive Officer - 2026-07-31
Director of Finance/CFO 55 2024-12-19
Chief Operating Officer - 2026-08-16
Director TitleAgeSince
Chairman 53 2026-07-31
Director/Board Member 64 2021-01-04
Director/Board Member - 2024-09-26
Date Insider Type Main position Quantity % Market Cap.
8/1/26 Option

Chief Executive Officer

200,000 0.2639%
8/1/26 Option

Founder

200,000 0.2639%
6/3/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.96%-31.58%-80.95% 28.37M
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.18%-0.76%+67.60%+93.46% 27.46B
Weighted average by Cap. -1.70%-1.06%+95.70%+133.60%

Financials

2024 2025
Net sales - -
Net income -13.19M -9.48M -8.19M -7.67M -7.01M -905M -13.26M -91.08M -35.49M -458M -35.63M -34.85M -1.52B -3.52M -2.53M -2.19M -2.05M -1.87M -242M -3.54M -24.31M -9.47M -122M -9.51M -9.3M -405M
Net Debt 1.69M 1.21M 1.05M 982K 898K 116M 1.7M 11.67M 4.55M 58.64M 4.56M 4.46M 194M 272K 195K 169K 158K 144K 18.64M 273K 1.88M 731K 9.43M 734K 718K 31.29M
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Employees
-
Date Price Change Volume
26-08-28 $0.5200 +1.96% 24,620
26-08-27 $0.5100 -5.56% 19,000
26-08-26 $0.5400 +5.88% 45,808
26-08-25 $0.5100 +2.00% 89,650
26-08-24 $0.5000 -1.96% 137,584